# Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

> **NCT03430518** · PHASE1 · COMPLETED · sponsor: **Amy Tiersten** · enrollment: 9 (actual)

## Conditions studied

- HER2-Negative Metastatic Breast Cancer
- Recurrent Ovarian Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT03430518
- **Lead sponsor:** Amy Tiersten
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-17
- **Primary completion:** 2020-02-10
- **Final completion:** 2020-02-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-08-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430518, "Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03430518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*